Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs UiPath Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $352.84 (market cap $9.39B), while UiPath Inc trades at $15.48 (market cap $8.08B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals.
| BIO | PATH | |
|---|---|---|
Market Cap | $9.39B | $8.08B |
Sector | Health | Technology |
52-Week High | $354.54 | $19.29 |
52-Week Low | $241.71 | $9.38 |
Enterprise Value | $9.14B | $6.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
UiPath (PATH) trades at $15.05, up 7.5% amid an AI stock rally, with technical indicators showing bullish momentum despite an overbought RSI. The company demonstrates strong revenue growth, improving from $892M in 2022 to $1.43B in 2025, with net income turning positive in 2026. Recent earnings show mixed results with Q1 2026 missing expectations, but Q3 and Q4 2025 beating estimates. Analyst sentiment remains cautious with a $13.33 consensus target below current price.
PATH offers exposure to enterprise automation growth with improving profitability, but faces execution risks and competitive pressures. The stock trades at premium valuations (P/E 25.08, P/S 4.86) while cash flow trends show improvement from negative $182M in 2025 to projected negative $67M in 2026. Key risks include AI competition and software spending volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
